SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

03 Aug 2022 Evaluate
Net sales declined -17.55%  to  Rs. 27324.90 million from Rs. 33141.20 millions.A radical decline of -81.86% was reported in the net profit of the company for the quarter ended June 2022 to Rs. 1171.80  millions from Rs. 6458.70 millions.Operating profit for the quarter ended June 2022 decreased to 2951.80 millions as compared to 9895.50 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 27324.90 33141.20 -17.55 27324.90 33141.20 -17.55 117716.70 110559.30 6.47
Other Income 853.10 516.80 65.07 853.10 516.80 65.07 2169.90 1290.90 68.09
PBIDT 2951.80 9895.50 -70.17 2951.80 9895.50 -70.17 4261.30 21731.50 -80.39
Interest 198.70 148.20 34.08 198.70 148.20 34.08 734.70 406.20 80.87
PBDT 2753.10 9747.30 -71.76 2753.10 9747.30 -71.76 3526.60 21325.30 -83.46
Depreciation 1303.50 1253.60 3.98 1303.50 1253.60 3.98 5141.90 5028.30 2.26
PBT 1449.60 8493.70 -82.93 1449.60 8493.70 -82.93 -1615.30 16297.00 -109.91
TAX 277.80 2035.00 -86.35 277.80 2035.00 -86.35 271.70 3710.80 -92.68
Deferred Tax -11.60 -30.60 -62.09 -11.60 -30.60 -62.09 -306.30 82.30 -472.17
PAT 1171.80 6458.70 -81.86 1171.80 6458.70 -81.86 -1887.00 12586.20 -114.99
Equity 909.30 907.80 0.17 909.30 907.80 0.17 909.00 907.40 0.18
PBIDTM(%) 10.80 29.86 -63.82 10.80 29.86 -63.82 3.62 19.66 -81.58

Lupin Share Price

2328.60 4.35 (0.19%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×